Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Flavone acetic acid (FAA), 8.6 gm-2 has been administered by 6h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in either disease.
Kerr
D J
DJ
CRC Department of Medical Oncology, University of Glasgow, UK.
Maughan
T
T
Newlands
E
E
Rustin
G
G
Bleehen
N M
NM
Lewis
C
C
Kaye
S B
SB
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005419:Flavonoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged
D000970:Antineoplastic Agents; D005419:Flavonoids; C049328:flavone acetic acid